Delving into the Latest Updates on Bio-Entai (Shanghai) Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Digestive System Disorders

Antibody drug conjugate (ADC)

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Infectious Diseases	1

Top 5 Drug Type	Count

Antibody drug conjugate (ADC)	2
Bispecific antibody	1

Top 5 Target	Count

HER2 x Top I	1
PDL1 x VEGF-A	1
EGFR x HER3	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

2

IND Approval

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DB-1303 ( HER2 x Top I )	Breast Cancer More	Phase 2 Clinical
YL-202 ( HER3 x Top I )	Advanced Lung Non-Small Cell Carcinoma More	IND Approval
PM-8002 ( PDL1 x VEGF-A )	Advanced Lung Non-Small Cell Carcinoma More	IND Approval
PM1300 ( EGFR x HER3 )	-	IND Application